Bond.az - NervGen Pharma Corp (NASDAQ:NGEN) shares dropped 39.7% in premarket Friday after announcing a dilutive public offering.
The clinical-stage biopharmaceutical company priced an offering of 24 million common shares at $2.50 each, plus warrants for another 24 million shares at $3.68, exercisable for five years.
Expected gross proceeds are around $60 million. The deal is set to close May 26, 2026.
Funds will be used to advance the NVG-291 candidate through clinical studies and for corporate purposes.












